72 related articles for article (PubMed ID: 15184821)
1. Management of patients with chronic hepatitis C virus infection and previous nonresponse.
Shiffman ML
Rev Gastroenterol Disord; 2004; 4 Suppl 1():S22-30. PubMed ID: 15184821
[TBL] [Abstract][Full Text] [Related]
2. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis C in patients with decompensated cirrhosis.
Everson GT
Rev Gastroenterol Disord; 2004; 4 Suppl 1():S31-8. PubMed ID: 15184823
[TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis C: management of treatment failures.
Keeffe EB
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S102-5. PubMed ID: 16234055
[TBL] [Abstract][Full Text] [Related]
5. Retreatment of chronic hepatitis C virus infection.
Lim JK; Imperial JC; Keeffe EB
Rev Gastroenterol Disord; 2004; 4(3):97-103. PubMed ID: 15359210
[TBL] [Abstract][Full Text] [Related]
6. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
7. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
Moucari R; Ripault MP; Oulès V; Martinot-Peignoux M; Asselah T; Boyer N; El Ray A; Cazals-Hatem D; Vidaud D; Valla D; Bourlière M; Marcellin P
J Hepatol; 2007 Apr; 46(4):596-604. PubMed ID: 17218037
[TBL] [Abstract][Full Text] [Related]
8. Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.
Shiffman ML
Curr Gastroenterol Rep; 2006 Feb; 8(1):46-52. PubMed ID: 16510034
[TBL] [Abstract][Full Text] [Related]
9. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
Reddy KR; Shiffman ML; Morgan TR; Zeuzem S; Hadziyannis S; Hamzeh FM; Wright TL; Fried M
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):124-9. PubMed ID: 17196435
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
11. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
Davis GL; Wong JB; McHutchison JG; Manns MP; Harvey J; Albrecht J
Hepatology; 2003 Sep; 38(3):645-52. PubMed ID: 12939591
[TBL] [Abstract][Full Text] [Related]
12. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Shiffman ML; Ghany MG; Morgan TR; Wright EC; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Gretch DR
Gastroenterology; 2007 Jan; 132(1):103-12. PubMed ID: 17241864
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
14. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
15. Into the light: strategies for battling hepatitis C.
Bacon BR; McHutchison JG
Am J Manag Care; 2007 Dec; 13 Suppl 12():S319-26. PubMed ID: 18095780
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial results of peginterferons in combination with ribavirin.
Craxi A; Licata A
Semin Liver Dis; 2003; 23 Suppl 1():35-46. PubMed ID: 12934167
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
[TBL] [Abstract][Full Text] [Related]
19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
20. Viral factors affecting the outcome of therapy for chronic hepatitis C.
Fried MW
Rev Gastroenterol Disord; 2004; 4 Suppl 1():S8-S13. PubMed ID: 15184819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
